Figures
- FIGURE 1
The modified Delphi process used in the study.
- FIGURE 2
Delphi consensus for initial therapy and adjustments in therapy of pulmonary sarcoidosis. Bold indicates statements that reached consensus. #: dose decrease to find the lowest dose that provides satisfactory symptom relief and disease control.
- FIGURE 3
Likert scale consensus scores on use of selected non-biologic immunomodulators and biologic therapies. Bold indicates statements that reached consensus. MTX: methotrexate.
- FIGURE 4
Treatment algorithm for symptomatic or organ-threatening sarcoidosis derived from the Delphi consensus recommendations. MTX: methotrexate; TNF-α: tumour necrosis factor-α; CLEAR: concomitant levofloxacin, ethambutol, azithromycin and rifampin; RCI: repository corticotrophin injection. #: consider hydroxychloroquine in cases of hypercalcemia or skin disease; ¶: alternatives considered that did not reach consensus: azathioprine, mycophenolate, leflunomide; +: alternatives considered that did not reach consensus: adalimumab, rituximab.
Tables
- TABLE 1
Characteristics of the Delphi panellists
Characteristic Panellists n Specialty# Pulmonology 19 Critical care 3 Rheumatology 2 Cardiology 1 Oncology 1 Experience treating sarcoidosis¶ 6–10 years 5 11–20 years 8 >20 years 8 Patients with sarcoidosis treated in entire career¶ ≤500 7 501–1000 8 1001–3000 3 >3000 2 Patients with sarcoidosis treated last year¶ ≤50 7 51–100 8 101–300 3 >300 2 #: highest degree of specialty is reported; ¶: some panellists did not respond to these questions.
Supplementary Material
Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.
Supplementary_appendix ERR-0146-2019_Supplementary_appendix
